Courtenay-Luck N S, Epenetos A A, Moore R, Larche M, Pectasides D, Dhokia B, Ritter M A
Cancer Res. 1986 Dec;46(12 Pt 1):6489-93.
Human anti-mouse immunoglobulin immune responses were studied in ten patients, eight with ovarian cancer and two with grade IV gliomas, diagnosed and treated with radiolabeled (123I, 131I) murine monoclonal antibodies. It was found that serum from these patients before treatment and from 18 control healthy individuals contained detectable antibodies to antigenic determinants on the Fc but not the F(ab')2 portion of mouse immunoglobulin. No change in this reactivity occurred after the initial (imaging) dose of monoclonal antibodies. However, repeated administration of mouse immunoglobulins for therapy resulted in an elevated immune response directed against determinants on both Fc and F(ab')2 regions of mouse immunoglobulin. This response contained increased levels of immunoglobulin M as well as immunoglobulin G and showed a marked prozone effect in our enzyme linked immunosorbent assay system. None of the immunized patients developed a detectable antiidiotypic response.
对10例患者的人抗小鼠免疫球蛋白免疫反应进行了研究，其中8例为卵巢癌患者，2例为IV级神经胶质瘤患者，这些患者均用放射性标记（123I、131I）的鼠单克隆抗体进行诊断和治疗。结果发现，这些患者治疗前的血清以及18名健康对照个体的血清中均含有可检测到的针对小鼠免疫球蛋白Fc段而非F(ab')2段抗原决定簇的抗体。在初始（成像）剂量的单克隆抗体给药后，这种反应性没有变化。然而，重复给予小鼠免疫球蛋白进行治疗会导致针对小鼠免疫球蛋白Fc段和F(ab')2段决定簇的免疫反应增强。这种反应中免疫球蛋白M以及免疫球蛋白G的水平升高，并且在我们的酶联免疫吸附测定系统中表现出明显的前带效应。免疫的患者均未产生可检测到的抗独特型反应。
